Verrica Pharmaceuticals(VRCA) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Verrica Pharmaceuticals Announces Resignation of Chief Legal Officer
TipRanksApr 25 16:49 ET
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating
Moomoo NewsApr 10 01:36 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Neutral on Verrica Pharmaceuticalsto Neutral
BenzingaApr 8 07:13 ET
Hold Rating on Verrica Pharmaceuticals Amid Liquidity Concerns and Uncertain Financial Strategy
TipRanksApr 8 06:16 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Verrica Pharmaceuticals (VRCA)
TipRanksApr 7 09:50 ET · Ratings
Verrica Pharmaceuticals Reports 16.7% Sequential Growth In Q1 2025 With Over 10,000 YCANTH Dispensed Applicator Units And Expects Revenue To Align With Normalized Distributor Inventory Levels
BenzingaApr 7 08:04 ET

Comments

Jaguar8

Jan 21 20:05

NEWS

$Verrica Pharmaceuticals (VRCA.US)$
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
Tuesday, 21st January at 7:00 am
– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315
– Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-3...

1

Jaguar8

Dec 6, 2024 21:00

NEWS

$Verrica Pharmaceuticals (VRCA.US)$
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
Friday, 6th December at 8:00 am
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its develop...

3

Teddy123

Oct 24, 2024 19:14

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology C

$Verrica Pharmaceuticals (VRCA.US)$
WEST CHESTER, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptanc...